+ Watch NGSX
on My Watchlist
A biopharmaceutical company, which focused on developing and commercializing novel pain management therapies.
NGSX has been on my watch list for ages, but was under the 100m market cap. So, I had to sit on my hands.With phase 3 trial "results" announced yesterday, it's now "pickable". [And no, I don't hate myself in the mirror today. It's the 24 hour delay thing. I would have rather bought yesterday].Pain patch. Chili peppers (don't laugh -- I'm a believer). Sufficient cash on hand to commercialize... or at least get er go'n. AND, the head honcho made "the street.com" look like monkeys. I know that may not be hard to do ... but it's done so infrequently ... as to merit some notice.Anyway, NGSX is for the speculative small cap portion of my portfolio. Hope it doesn't get bought out too soon.
Don't give up on this one yet. Big looser today on trial results. But, after digging underneath the headlines, I'm inclined to hang tight. Risky, yes. But, I already made my calculated wager. Don't blink now. This represents only a small portion of my speculative portfolio.
Oh well. Cleaning up after 2 year hiatus on CAPS
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions